Get the Stockscreener App
0.8369
3.02%
0.0245
Omega Therapeutics Inc stock is traded at $0.8369, with a volume of 180.69K.
It is up +3.02% in the last 24 hours and up +5.91% over the past month.
Omega Therapeutics Inc is a development-stage biotechnology company leveraging its proprietary epigenomic programming platform to biologically engineer a new class of programmable epigenetic medicines, known as Omega Epigenomic Controllers. Using epigenomic controllers, Omega is seeking to transform the practice of human medicine through selective and direct control of the human genome to treat and cure disease. It operates in the U.S.
See More
Previous Close:
$0.8124
Open:
$0.8
24h Volume:
180.69K
Relative Volume:
0.59
Market Cap:
$46.34M
Revenue:
$3.10M
Net Income/Loss:
$-97.43M
P/E Ratio:
-0.377
EPS:
-2.22
Net Cash Flow:
$-94.38M
1W Performance:
-13.63%
1M Performance:
+5.91%
6M Performance:
-61.96%
1Y Performance:
-62.80%
1-Day Range:
$0.7924
$0.88
1-Week Range:
$0.782
$0.98
52-Week Range:
$0.75
$6.30
Omega Therapeutics Inc Stock (OMGA) Company Profile
Name
Omega Therapeutics Inc
Sector
Industry
Phone
(617) 949-4360
Address
140 FIRST STREET, SUITE 501, CAMBRIDGE
Compare OMGA with other stocks
| Stocks | Price | Market Cap | Revenue | Net Income | Cash Flow | EPS |
|---|---|---|---|---|---|---|
OMGA
Omega Therapeutics Inc
|
0.8369 | 46.34M | 3.10M | -97.43M | -94.38M | -1.80 |
|
VRTX
Vertex Pharmaceuticals Inc
|
397.27 | 102.31B | 10.63B | -479.80M | -1.35B | -1.99 |
|
REGN
Regeneron Pharmaceuticals Inc
|
701.85 | 77.13B | 13.85B | 4.65B | 3.32B | 40.41 |
|
ARGX
Argen X Se Adr
|
623.82 | 37.30B | 1.86B | -40.29M | -1.28B | -0.85 |
|
ALNY
Alnylam Pharmaceuticals Inc
|
245.44 | 31.66B | 2.09B | -332.26M | 16.06M | -2.62 |
|
BNTX
Biontech Se Adr
|
113.08 | 27.11B | 3.30B | -501.07M | 1.03B | -2.1146 |
Omega Therapeutics Inc Stock (OMGA) Upgrades & Downgrades
| Date | Action | Analyst | Rating Change |
|---|---|---|---|
| Nov-15-24 | Downgrade | Raymond James | Outperform → Mkt Perform |
| Jun-18-24 | Initiated | Raymond James | Outperform |
| May-25-23 | Resumed | Jefferies | Buy |
| Dec-08-22 | Initiated | H.C. Wainwright | Buy |
| Sep-23-22 | Initiated | Chardan Capital Markets | Buy |
Omega Therapeutics Inc Stock (OMGA) Latest News
Layoff Tracker: Editas Will Cut 60% of Staff - BioSpace
Omega Therapeutics, Inc. Announces Board and Committee Changes - Marketscreener.com
Omega Therapeutics announces board changes By Investing.com - Investing.com Nigeria
Omega Therapeutics announces board changes - Investing.com India
Omega Therapeutics Appoints New Director Ravi Mehrotra - TipRanks
2024’s Busiest Dealmakers: Novartis Laps The Field, While Lilly, Sanofi Keep Busy - Citeline News & Insights
Omega Therapeutics, Inc. (OMGA) Reports Q3 Loss, Tops Revenue Estimates - MSN
Flagship Pioneering Appoints Angela Hwang as CEO-Partner and Chief Executive Officer of Metaphore Biotechnologies - Quantisnow
Flagship Pioneering Announces Two New Agreements with Ampersand Biomedicines and Montai Therapeutics Under its Strategic Partnership with Pfizer – Company Announcement - Financial Times
Piper Sandler Lowers Omega Therapeutics (NASDAQ:OMGA) Price Target to $4.00 - Defense World
Omega Therapeutics Reports Third Quarter 2024 Results - TipRanks
Omega Therapeutics Third Quarter 2024 Earnings: Revenues Beat Expectations, EPS In Line - Yahoo Finance
Omega Therapeutics stock target cut, keeps Overweight on clinical updates By Investing.com - Investing.com Canada
Shares of Flagship-founded biotech fall as CEO departs - The Business Journals
Omega Therapeutics (NASDAQ:OMGA) Downgraded to Market Perform Rating by Raymond James - MarketBeat
Piper Sandler Issues Pessimistic Forecast for Omega Therapeutics (NASDAQ:OMGA) Stock Price - MarketBeat
Omega Therapeutics Inc (OMGA) Quarterly 10-Q Report - Quartzy
Omega Therapeutics Names Kaan Certel as CEO - MarketWatch
Omega Therapeutics Announces Successful Completion of Phase - GlobeNewswire
Omega Therapeutics Announces Successful Completion of Phase 1 Trial for Novel Epigenomic Controller, Prioritized Pipeline, Leadership Changes, and Third Quarter 2024 Financial Results - The Manila Times
Omega Therapeutics, Inc. Announces Chief Executive Officer Changes - Marketscreener.com
Brian M. Alexander Joins Valo Health as Chief Executive Officer and Flagship Pioneering as CEO-Partner - Financial Times
Omega Therapeutics (NASDAQ:OMGA) Stock Price Down 0.9%Should You Sell? - MarketBeat
Global Alopecia Treatment Market is Anticipated to Surpass ~USD 4 Billion by 2030 | DelveInsight - GlobeNewswire
Oculis Holding AG (OCS) Moves 7.9% Higher: Will This Strength Last? - Yahoo Finance
Pre-market Movers: EVOK, HCTI, GLUE, MNPR... - RTTNews
State Street Corp's Strategic Acquisition in Omega Healthcare Investors Inc - Yahoo Finance
Zura Bio (NASDAQ:ZURA) versus Omega Therapeutics (NASDAQ:OMGA) Critical Contrast - Defense World
Omega Therapeutics stock hits 52-week low at $0.94 By Investing.com - Investing.com Australia
Cubist Systematic Strategies LLC Grows Holdings in Omega Therapeutics, Inc. (NASDAQ:OMGA) - Defense World
Omega Therapeutics to Present Multiple Posters Highlighting Versatile Platform Capabilities at Upcoming Scientific Meetings - The Manila Times
Omega Therapeutics to Present Multiple Posters Highlighting - GlobeNewswire
Flagship Pioneering Announces Appointment of Paul Parker as Managing Partner, Leading Capital Solutions - Financial Times
Omega Therapeutics stock hits 52-week low at $1.07 By Investing.com - Investing.com Australia
Omega Therapeutics stock hits 52-week low at $1.07 - Investing.com India
Omega Therapeutics Appoints New Director - Investing.com India
Omega Therapeutics Welcomes Robert Rosiello to Board - TipRanks
Omega Therapeutics Inc Stock (OMGA) Financials Data
Revenue
Net Income
Cash Flow
EPS
2.88%
2.65%
Open in Yahoo
|
Open in Google
|
Open in Finviz
|
Open in MarketWatch
|
Open in EDGAR
|
Open in Reuters
Cap:
|
Volume (24h):